In the latest trading session, 2.25 million IGC Pharma Inc (AMEX:IGC) shares changed hands as the company’s beta touched 1.27. With the company’s most recent per share price at $0.40 changing hands around $0.05 or 13.24% at last look, the market valuation stands at $30.33M. IGC’s current price is a discount, trading about -127.5% off its 52-week high of $0.91. The share price had its 52-week low at $0.25, which suggests the last value was 37.5% up since then. When we look at IGC Pharma Inc’s average trading volume, we note the 10-day average is 0.43 million shares, with the 3-month average coming to 290.74K.
Analysts gave the IGC Pharma Inc (IGC) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 1 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended IGC as a Hold, 1 felt it is a Buy and 0 rated the stock as Underweight. IGC Pharma Inc’s EPS for the current quarter is expected to be -0.03.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
IGC Pharma Inc (AMEX:IGC) trade information
Instantly IGC is in green as seen in intraday trades today. With action 16.84%, the performance over the past five days has been green. The company’s shares are showing year-to-date upside of 43.16%, with the 5-day performance at 16.84% in the green. However, in the 30-day time frame, IGC Pharma Inc (AMEX:IGC) is 13.05% up. Looking at the short shares, we see there were 1.03 million shares sold at short interest cover period of 2.85 days.
IGC Pharma Inc (IGC) estimates and forecasts
Data shows that the IGC Pharma Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -15.76% over the past 6 months, a 40.91% in annual growth rate that is considerably higher than the industry average of 20.30%. Year-over-year growth is forecast to reach -16.00% down from the last financial year.
Consensus estimates given by 2 financial analysts project the company’s revenue in the current quarter to hit an average of 300k. 2 analysts are of the opinion that IGC Pharma Inc’s revenue for the current quarter will be 250k.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -13.79%. The 2024 estimates are for IGC Pharma Inc earnings to increase by 43.18%.
IGC Dividends
IGC Pharma Inc is expected to release its next quarterly earnings report on 2024-Nov-07.
IGC Pharma Inc (AMEX:IGC)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 7.92% of IGC Pharma Inc shares while 21.66% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 23.52%. There are 21.66% institutions holding the IGC Pharma Inc stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 1.1961% of the shares, roughly 0.7 million IGC shares worth $0.31 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 1.0965% or 0.65 million shares worth $0.28 million as of 2024-06-30.
